先天性心脏病患者以心室辅助装置桥接心脏移植的移植结局
本研究基于2006至2015年器官共享联合网络数据库的21865例心脏移植受者,将患者按有无先天性心脏病(CHD)和有无心室辅助装置(VAD)支持分为四组。结果显示,CHD且使用VAD桥接移植的患者术前病情更重,但移植后1年与5年生存率与CHD未使用VAD者及其他非CHD移植患者相似。
要点
- 在1871例CHD患者中,143例(7.6%)使用VAD桥接移植。
- CHD且使用VAD者较CHD未使用VAD者术前功能状态更差、感染更多、致敏比例更高。
- CHD且使用VAD者移植后1年及5年生存率与CHD未使用VAD者及其他非CHD移植患者相似。
核心结论
- CHD患者使用VAD桥接移植虽然术前病情更重,但移植后生存率与CHD未使用VAD者及其他非CHD心脏移植患者相似。
- VAD支持可能减轻CHD这一困难队列中某些导致移植后不良结局的危险因素。
研究设计与样本
- 回顾性队列研究,基于2006至2015年器官共享联合网络数据库全部心脏移植受者(n=21865)。
- 按有无CHD诊断和有无VAD支持分为四组:+CHD/+VAD、+CHD/-VAD、+VAD/-CHD、-VAD/-CHD。
- 比较+CHD/+VAD与+CHD/-VAD的移植前特征,并比较+CHD/+VAD与其余三组的移植后生存率。
主要发现
- 1871例(8.6%)患者有CHD,其中1348例(72%)年龄小于18岁,143例(7.6%)使用VAD桥接移植。
- +CHD/+VAD组较+CHD/-VAD组功能状态更差(<50%:60% vs 46%,p=0.004)。
- +CHD/+VAD组较+CHD/-VAD组感染更多(29% vs 14%,p<0.001),致敏比例更高(47% vs 30%,p<0.001)。
- +CHD/+VAD组较+CHD/-VAD组更多需要呼吸机支持(20% vs 13%,p=0.029)和透析(13% vs 2.5%,p<0.001)。
- +CHD/+VAD组与+CHD/-VAD组1年生存率(84% vs 87%)和5年生存率(72% vs 75%)相似(p=0.694);与-CHD/+VAD组(n=7363,p=0.529)和-CHD/-VAD组(n=12613,p=0.097)比较生存率也相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ventricular assist device (VAD) use as a bridge to transplant (BTT) for children with end-stage heart failure and congenital heart disease (CHD), although challenging, has increased, but its effect on posttransplant outcome is unknown. This study describes posttransplant outcomes of CHD patients BTT with a VAD. METHODS: All heart transplant recipients identified in United Network of Organ Sharing database from 2006 to 2015 (n = 21,865) were divided into four groups by those with (+) and without (-) a diagnosis of CHD and with (+) and without (-) VAD support at transplant: +CHD/+VAD, +CHD/-VAD, +VAD/-CHD, and -VAD/-CHD. Posttransplant survival of +CHD/+VAD was compared with +CHD/-VAD, -CHD/+VAD, and -CHD/-VAD in addition to pretransplant characteristics comparison between +CHD/+VAD and +CHD/-VAD. RESULTS: Of 1,871 patients (8.6%) with CHD, 1,348 (72%) were younger than 18 years old, and 143 (7.6%) were BTT with a VAD (+CHD/+VAD). At transplant, +CHD/+VAD compared with +CHD/-VAD were more likely to have worse functional status (<50%: 60% vs 46%, p = 0.004), infections (29% vs 14%, p < 0.001), to be sensitized (47% vs 30%, p < 0.001) and on ventilator support (20% vs 13%, p = 0.029) and dialysis (13% vs 2.5%, p < 0.001). Overall, 1-year (84% vs 87%) and 5-year (72% vs 75%) survival was similar for +CHD/+VAD and +CHD/-VAD (p = 0.694). Survival was also similar when +CHD/+VAD were compared with -CHD/+VAD (n = 7,363; p = 0.529) and -CHD/-VAD (n = 12,613; p = 0.097). CONCLUSIONS: Although more ill pretransplant, CHD patients BTT with a VAD have similar posttransplant survival compared with CHD patients without a VAD and with other non-CHD heart transplant patients. VAD support may mitigate certain risk factors for poor posttransplant outcomes in the challenging CHD cohort.
引用
- Bryant R, Rizwan R, Villa CR, et al. Transplant Outcomes for Congenital Heart Disease Patients Bridged With a Ventricular Assist Device. Ann Thorac Surg. 2018. PMID: 29723531. doi:10.1016/j.athoracsur.2018.03.060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。